Share on StockTwits

Foundation Medicine (NYSE:FMI) COO Steven J. Kafka unloaded 5,000 shares of the company’s stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $25.19, for a total value of $125,950.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on FMI. Analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday, June 25th. They set a “neutral” rating and a $28.00 price target on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th. Finally, analysts at William Blair initiated coverage on shares of Foundation Medicine in a research note on Thursday, April 17th. They set a “market perform” rating on the stock. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $38.80.

Shares of Foundation Medicine (NYSE:FMI) traded up 3.37% during mid-day trading on Monday, hitting $26.96. The stock had a trading volume of 292,305 shares. Foundation Medicine has a one year low of $19.513 and a one year high of $45.00. The stock’s 50-day moving average is $23.08 and its 200-day moving average is $28.33. The company’s market cap is $760.1 million.

Foundation Medicine (NYSE:FMI) last released its earnings data on Wednesday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.04. The company had revenue of $11.45 million for the quarter, compared to the consensus estimate of $11.33 million. The company’s revenue for the quarter was up 120.2% on a year-over-year basis. On average, analysts predict that Foundation Medicine will post $-1.82 earnings per share for the current fiscal year.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.